Drug |
Interaction |
Acetylsalicylic acid |
Acetylsalicylic acid may reduce the efficacy of Trandolapril. Monitor for changes in Trandolapril efficacy if Acetylsalicylic acid is initiated, discontinued or dose changed. |
Allopurinol |
The ACE inhibitor, Trandolapril, may increase the risk of hypersensitivity reactions to Allopurinol. |
Amifostine |
Trandolapril may increase the hypotensive effect of Amifostine. At chemotherapeutic doses of Amifostine, Trandolapril should be withheld for 24 hours prior to Amifostine administration. Use caution at lower doses of Amifostine. |
Amiloride |
Increased risk of hyperkalemia. Monitor serum potassium levels. |
Aminosalicylic Acid |
The salicylate, Aminosalicylic acid, may reduce the efficacy of Trandolapril. Monitor for changes in Trandolapril efficacy if Aminosalicylic acid is initiated, discontinued or dose changed. |
Azathioprine |
Trandolapril may increase the risk of neutropenia. Monitor for increased toxic effects of Azathioprine if Trandolapril is initiated or dose increased. |
Azilsartan medoxomil |
Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment. |
Bendroflumethiazide |
The thiazide diuretic, Bendroflumethiazide, may increase the hypotensive effect of Trandolapril. Bendroflumethiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. |
Benzphetamine |
Benzphetamine may reduce the efficacy of Trandolapril. |
Bumetanide |
The loop diuretic, Bumetanide, may increase the hypotensive effect of Trandolapril. Bumetanide may also increase the nephrotoxicity of Trandolapril. |
Candesartan |
The angiotensin II receptor blocker, Candesartan, may increase the adverse effects of Trandolapril. |
Celecoxib |
The NSAID, Celecoxib, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Celecoxib is initiated, discontinued or dose changed. |
Chlorothiazide |
The thiazide diuretic, Chlorothiazide, may increase the hypotensive effect of Trandolapril. Chlorothiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. |
Chlorthalidone |
The thiazide diuretic, Chlorthalidone, may increase the hypotensive effect of Trandolapril. Chlorthalidone may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. |
Cyclosporine |
The ACE inhibitor, Trandolapril, may increase the nephrotoxicity of Cyclosporine. |
Dextroamphetamine |
Dextroamphetamine may reduce the efficacy of Trandolapril. |
Diazoxide |
Diazoxide may increase the hypotensive effect of Trandolapril. Monitor for changes in blood pressure. |
Diclofenac |
The NSAID, Diclofenac, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Diclofenac is initiated, discontinued or dose changed. |
Diflunisal |
The NSAID, Diflunisal, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Diflunisal is initiated, discontinued or dose changed. |
Drospirenone |
Increased risk of hyperkalemia. Monitor serum potassium levels. |
Ephedra |
Ephedra may antagonize the antihypertensive effect of Trandolapril. Monitor Trandolapril efficacy. |
Eplerenone |
Increased risk of hyperkalemia. Monitor serum potassium levels. |
Epoprostenol |
The prostacyclin analogue, Epoprostenol, may increase the hypotensive effect of Trandolapril. |
Eprosartan |
The angiotensin II receptor blocker, Eprosartan, may increase the adverse effects of Trandolapril. |
Ethacrynic acid |
The loop diuretic, Ethacrynic acid, may increase the hypotensive effect of Trandolapril. Ethacrynic acid may also increase the nephrotoxicity of Trandolapril. |
Etodolac |
The NSAID, Etodolac, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Etodolac is initiated, discontinued or dose changed. |
Fenoprofen |
The NSAID, Fenoprofen, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Fenoprofen is initiated, discontinued or dose changed. |
Flurbiprofen |
The NSAID, Flurbiprofen, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Flurbiprofen is initiated, discontinued or dose changed. |
Furosemide |
The loop diuretic, Furosemide, may increase the hypotensive effect of Trandolapril. Furosemide may also increase the nephrotoxicity of Trandolapril. |
Ginseng |
Ginseng may antagonize the antihypertensive effect of Trandolapril. Monitor Trandolapril efficacy. |
Hydrochlorothiazide |
The thiazide diuretic, Hydrochlorothiazide, may increase the hypotensive effect of Trandolapril. Hydrochlorothiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. |
Hydroflumethiazide |
The thiazide diuretic, Hydroflumethiazide, may increase the hypotensive effect of Trandolapril. Hydroflumethiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. |
Ibuprofen |
The NSAID, Ibuprofen, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Ibuprofen is initiated, discontinued or dose changed. |
Icatibant |
Icatibant may attenuate the antihypertensive effect of ACE inhibitors by pharmacodynamic antagonism. Monitor concomitant therapy closely. |
Iloprost |
The prostacyclin analogue, Iloprost, may increase the hypotensive effect of Trandolapril. |
Indapamide |
The thiazide diuretic, Indapamide, may increase the hypotensive effect of Trandolapril. Indapamide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. |
Indomethacin |
The NSAID, Indomethacin, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Indomethacin is initiated, discontinued or dose changed. |
Irbesartan |
The angiotensin II receptor blocker, Irbesartan, may increase the adverse effects of Trandolapril. |
Ketoprofen |
The NSAID, Ketoprofen, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Ketoprofen is initiated, discontinued or dose changed. |
Ketorolac |
The NSAID, Ketorolac, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Ketorolac is initiated, discontinued or dose changed. |
Lisdexamfetamine |
Lisdexamfetamine may reduce the efficacy of Trandolapril. |
Lithium |
Trandolapril may increase the serum concentration of Lithium increasing the risk of Lithium toxicity. Monitor for changes in Lithium serum concentrations, toxicity and efficacy if Trandolapril is initiated, discontinued or dose changed. |
Losartan |
The angiotensin II receptor blocker, Losartan, may increase the adverse effects of Trandolapril. |
Lumiracoxib |
The NSAID, Lumiracoxib, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Lumiracoxib is initiated, discontinued or dose changed. |
Meclofenamic acid |
The NSAID, Meclofenamate, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Meclofenamate is initiated, discontinued or dose changed. |
Mefenamic acid |
The NSAID, Mefenamic acid, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Mefenamic acid is initiated, discontinued or dose changed. |
Meloxicam |
The NSAID, Meloxicam, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Meloxicam is initiated, discontinued or dose changed. |
Methamphetamine |
Methamphetamine may reduce the efficacy of Trandolapril. |
Methyclothiazide |
The thiazide diuretic, Methyclothiazide, may increase the hypotensive effect of Trandolapril. Methyclothiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. |
Methylphenidate |
Methylphenidate may antagonize the antihypertensive effect of Trandolapril. Monitor for changes in blood pressure if Methylphenidate is initiated, discontinued or dose changed. |
Metolazone |
The thiazide diuretic, Metolazone, may increase the hypotensive effect of Trandolapril. Metolazone may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. |
Nabumetone |
The NSAID, Nabumetone, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Nabumetone is initiated, discontinued or dose changed. |
Naproxen |
The NSAID, Naproxen, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Naproxen is initiated, discontinued or dose changed. |
Olmesartan |
The angiotensin II receptor blocker, Olmesartan, may increase the adverse effects of Trandolapril. |
Oxaprozin |
The NSAID, Oxaprozin, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Oxaprozin is initiated, discontinued or dose changed. |
Phendimetrazine |
Phendimetrazine may reduce the efficacy of Trandolapril. |
Phentermine |
Phentermine may reduce the efficacy of Trandolapril. |
Piroxicam |
The NSAID, Piroxicam, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Piroxicam is initiated, discontinued or dose changed. |
Polythiazide |
The thiazide diuretic, Polythiazide, may increase the hypotensive effect of Trandolapril. Polythiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. |
Potassium |
Increased risk of hyperkalemia |
Potassium Chloride |
The potassium salt may increase the hyperkalemic effect of Trandolapril. |
Quinine |
May cause additive hypotensive effects. Monitor for changes in blood pressure if Quinine is initiated, discontinued or dose changed. |
Rituximab |
Trandolapril may incresae the hypotensive effect of Rituximab. |
Salsalate |
The salicylate, Salsalate, may reduce the efficacy of Trandolapril. Monitor for changes in Trandolapril efficacy if Salsalate is initiated, discontinued or dose changed. |
Sirolimus |
Increased risk of angioedema. Monitor for signs and symptoms of facial and systemic edema and/or erythema. |
Sodium bicarbonate |
Sodium bicarbonate may decrease the absorption of Trandolapril. Administration should be spaced. |
Spironolactone |
Increased risk of hyperkalemia. Monitor serum potassium levels. |
Sulindac |
The NSAID, Sulindac, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Sulindac is initiated, discontinued or dose changed. |
Telmisartan |
The angiotensin II receptor blocker, Telmisartan, may increase the adverse effects of Trandolapril. |
Temsirolimus |
Increased risk of angioedema. Monitor for signs and symptoms of facial and systemic edema and/or erythema. |
Tiaprofenic acid |
The NSAID, Tiaprofenic acid, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Tiaprofenic acid is initiated, discontinued or dose changed. |
Tizanidine |
Tizanidine increases the risk of hypotension with the ACE inhibitor |
Tolmetin |
The NSAID, Tolmetin, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Tolmetin is initiated, discontinued or dose changed. |
Torasemide |
The loop diuretic, Torasemide, may increase the hypotensive effect of Trandolapril. Torasemide may also increase the nephrotoxicity of Trandolapril. |
Treprostinil |
The prostacyclin analogue, Treprostinil, may increase the hypotensive effect of Trandolapril. |
Triamterene |
Increased risk of hyperkalemia. Monitor serum potassium levels. |
Trichlormethiazide |
The thiazide diuretic, Trichlormethiazide, may increase the hypotensive effect of Trandolapril. Trichlormethiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. |
Trimethoprim |
Increased risk of hyperkalemia. Monitor serum potassium levels. |
Valsartan |
The angiotensin II receptor blocker, Valsartan, may increase the adverse effects of Trandolapril. |